

Supplementary Table 5. Associations between single-nucleotide polymorphism (SNP) rs6626269 or rs4778137 and overall survival in the validation data set: study-specific unadjusted analyses*

Study	rs6626269		rs4778137		rs4778137 (ER negative)		rs4778137 (ER positive)	
	HR (95% CI)	P_{trend}	HR (95% CI)	P_{trend}	HR (95% CI)	P_{trend}	HR (95% CI)	P_{trend}
BBCC	N/A†		1.11 (0.88 to 1.39)	.39	0.89 (0.57 to 1.40)	.61	1.25 (0.91 to 1.74)	.17
CGPS	0.92 (0.75 to 1.14)	.46	0.94 (0.78 to 1.13)	.52	0.77 (0.53 to 1.13)	.19	0.97 (0.76 to 1.24)	.80
CNIO-BCS	1.08 (0.31 to 3.74)	.90	1.19 (0.43 to 3.32)	.74	3.01 (0.29 to 30.70)	.35	1.79 (0.33 to 9.85)	.50
GESBC	N/A†		0.96 (0.71 to 1.31)	.81	0.92 (0.58 to 1.47)	.72	0.80 (0.48 to 1.33)	.40
HEBCS	1.09 (0.92 to 1.29)	.32	1.05 (0.88 to 1.26)	.60	0.89 (0.63 to 1.25)	.51	1.10 (0.88 to 1.37)	.41
KARBAC	0.82 (0.55 to 1.20)	.31	0.92 (0.65 to 1.30)	.64	0.96 (0.49 to 1.86)	.90	0.89 (0.58 to 1.35)	.57
KBCP	1.07 (0.85 to 1.35)	.58	1.06 (0.82 to 1.37)	.64	0.61 (0.35 to 1.07)	.09	1.17 (0.87 to 1.58)	.29
kConFab/AOCS	1.44 (0.78 to 2.67)	.24	0.93 (0.50 to 1.72)	.82	1.89 (0.35 to 10.16)	.46	0.86 (0.35 to 2.13)	.74
MCBCS	0.91 (0.54 to 1.54)	.72	0.89 (0.55 to 1.46)	.65	1.24 (0.56 to 2.74)	.59	0.63 (0.32 to 1.25)	.18
MCCS	1.17 (0.80 to 1.70)	.41	0.83 (0.57 to 1.19)	.30	0.39 (0.18 to 0.86)	.02	1.22 (0.79 to 1.90)	.37
ORIGO	1.25 (0.92 to 1.69)	.15	0.84 (0.62 to 1.13)	.24	1.11 (0.65 to 1.88)	.71	0.69 (0.43 to 1.10)	.12
PBCS	1.00 (0.80 to 1.26)	.97	0.98 (0.81 to 1.20)	.88	0.93 (0.75 to 1.16)	.55	0.96 (0.76 to 1.20)	.53
SASBAC	0.91 (0.68 to 1.21)	.52	0.79 (0.60 to 1.04)	.10	1.03 (0.50 to 2.10)	.94	0.70 (0.49 to 1.00)	.05
SBCS	0.80 (0.54 to 1.20)	.28	0.98 (0.70 to 1.37)	.90	0.98 (0.51 to 1.88)	.94	1.10 (0.63 to 1.90)	.75
UCIBCS	N/A‡		1.04 (0.88 to 1.23)	.65	0.74 (0.50 to 1.10)	.13	1.10 (0.88 to 1.38)	.41

* Statistical significance based on one degree of freedom trend test. All statistical tests were two-sided. HR = hazard ratio; CI = confidence interval; ER = estrogen receptor; BBCC = Bavarian Breast Cancer Cases and Controls; CGPS = Copenhagen Breast Cancer Study and General Population Study; CNIO-BCS = Spanish National Cancer Centre Breast Cancer Study; GESBC = Genetic Epidemiology Study of Breast Cancer by Age 50; HEBCS = Helinski Breast Cancer Study; KARBAC = Karolinska Breast Cancer Study; KBCP = Kuopio Breast Cancer Project; kConFab/AOCS = Kathleen Cuninghame Foundation Consortium for Familial Breast Cancer (kConFab) and Australian Ovarian Cancer Study (AOCS); MCBCS = Mayo Clinic Breast Cancer Study; MCCS = Melbourne Collaborative Cohort Study; ORIGO = Leiden University Medical Centre Breast Cancer Study; PBCS = National Cancer Institute Polish Breast Cancer Study; SASBAC = Singapore and Sweden Breast Cancer Study; SBCS = Sheffield Breast Cancer Study; UCIBCS = University of California at Irvine Breast Cancer Study

† SNP assay failed quality control requirements.

‡ Failed SNP assay.